![](/sites/default/files/styles/article_actu_main_image/public/2023-09/actu-malaisie.jpg?itok=6JGZzXaH)
Company joins exclusive club of pioneering B Corp-certified pharmaceutical companies
![](/sites/default/files/styles/article_actu_main_image/public/2023-09/actu-malaisie.jpg?itok=6JGZzXaH)
Opening will enable pharmaceutical company to better provide UK market with direct distribution and client-facing team. UK third direct-selling country for Provepharm, after France and the United States, expanding commercial presence in medical dye and antidote markets
![](/sites/default/files/styles/article_actu_main_image/public/2023-09/actu-malaisie.jpg?itok=6JGZzXaH)
Provepharm, an international, private and sustainable pharmaceutical company specialized in revitalizing molecules and Pharm-D, a healthcare and pharmaceutical company based in Malaysia with a strong foothold in Singapore, announce today their partnership to launch Proveblue® 5 mg/ml solution for injection in Malaysia.
![](/sites/default/files/styles/article_actu_main_image/public/2022-07/Banni%C3%A8re-vide-nouvelle-identit%C3%A9-bleue.jpg?itok=RuCO4wgg)
Provepharm receives FDA approval for BLUDIGO™ (indigotindisulfonate sodium, USP) Injection
![](/sites/default/files/styles/article_actu_main_image/public/2020-12/Fond_Vide_BC02.png?itok=xHS6wOPl)
Following GMP certification earned in 2019 for its new production unit, Provepharm now has full control over its production chain for Europe and the US.
![](/sites/default/files/styles/article_actu_main_image/public/2020-12/Fond_Vide_BC02.png?itok=xHS6wOPl)
![](/sites/default/files/styles/article_actu_main_image/public/2020-12/Fond_Vide_BC02.png?itok=xHS6wOPl)
New round of funding enables pharma company to make major steps forward in its Horizon 2025 strategy.